Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly (Q54316519)
Jump to navigation
Jump to search
scientific article published on 19 November 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly |
scientific article published on 19 November 2014 |
Statements
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly (English)
1 reference
1 reference
Julie M Vose
1 reference
Pau Abrisqueta
1 reference
Kyriakos P Papadopoulos
1 reference
Coumaran Egile
1 reference
Rodrigo Ruiz-Soto
1 reference
Jason Jiang
1 reference
Weiliang Shi
1 reference
Frauke Bentzien
1 reference
Drew Rasco
1 reference
19 November 2014
1 reference
56
1 reference
6
1 reference
1763-1770
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference